Literature DB >> 20876353

Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis.

Timothy W Phares1, Stephen A Stohlman, David R Hinton, Roscoe Atkinson, Cornelia C Bergmann.   

Abstract

The T cell inhibitory ligand B7-H1 hinders T cell-mediated virus control, but also ameliorates clinical disease during autoimmune and virus-induced CNS disease. In mice infected with gliatropic demyelinating coronavirus, B7-H1 expression on oligodendroglia delays virus control, but also dampens clinical disease. To define the mechanisms by which B7-H1 alters pathogenic outcome, virus-infected B7-H1-deficient (B7-H1(-/-)) mice were analyzed for altered peripheral and CNS immune responses. B7-H1 deficiency did not affect peripheral T or B cell activation or alter the magnitude or composition of CNS-infiltrating cells. However, higher levels of IFN-γ mRNA in CNS-infiltrating virus-specific CD8 T cells as well as CD4 T cells contributed to elevated IFN-γ protein in the B7-H1(-/-) CNS. Increased effector function at the single-cell level was also evident by elevated granzyme B expression specifically in virus-specific CNS CD8 T cells. Although enhanced T cell activity accelerated virus control, 50% of mice succumbed to infection. Despite enhanced clinical recovery, surviving B7-H1(-/-) mice still harbored persisting viral mRNA, albeit at reduced levels compared with wild-type mice. B7-H1(-/-) mice exhibited extensive loss of axonal integrity, although demyelination, a hallmark of virus-induced tissue damage, was not increased. The results suggest that B7-H1 hinders viral control in B7-H1 expressing glia cells, but does not mediate resistance to CD8 T cell-mediated cytolysis. These data are the first, to our knowledge, to demonstrate that B7-H1-mediated protection from viral-induced immune pathology associated with encephalomyelitis resides in limiting T cell-mediated axonal bystander damage rather than direct elimination of infected myelinating cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876353      PMCID: PMC3159959          DOI: 10.4049/jimmunol.1001984

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  86 in total

1.  B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

Authors:  Haidong Dong; Gefeng Zhu; Koji Tamada; Dallas B Flies; Jan M A van Deursen; Lieping Chen
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

2.  Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies.

Authors:  J O Fleming; M D Trousdale; F A el-Zaatari; S A Stohlman; L P Weiner
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

Authors:  Yvette E Latchman; Spencer C Liang; Yin Wu; Tatyana Chernova; Raymond A Sobel; Martina Klemm; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

4.  Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.

Authors:  Bettina Schreiner; Meike Mitsdoerffer; Bernd C Kieseier; Lieping Chen; Hans-Peter Hartung; Michael Weller; Heinz Wiendl
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

5.  Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein.

Authors:  D Martin; S L Near; A Bendele; D A Russell
Journal:  Exp Neurol       Date:  1995-02       Impact factor: 5.330

6.  Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase.

Authors:  W Zhao; R G Tilton; J A Corbett; M L McDaniel; T P Misko; J R Williamson; A H Cross; W F Hickey
Journal:  J Neuroimmunol       Date:  1996-02       Impact factor: 3.478

7.  Sequential infection of glial cells by the murine hepatitis virus JHM strain (MHV-4) leads to a characteristic distribution of demyelination.

Authors:  F I Wang; D R Hinton; W Gilmore; M D Trousdale; J O Fleming
Journal:  Lab Invest       Date:  1992-06       Impact factor: 5.662

8.  Tumor necrosis factor expression during mouse hepatitis virus-induced demyelinating encephalomyelitis.

Authors:  S A Stohlman; D R Hinton; D Cua; E Dimacali; J Sensintaffar; F M Hofman; S M Tahara; Q Yao
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis.

Authors:  Y Okuda; Y Nakatsuji; H Fujimura; H Esumi; T Ogura; T Yanagihara; S Sakoda
Journal:  J Neuroimmunol       Date:  1995-10       Impact factor: 3.478

10.  Expression of the inducible nitric oxide synthase. Correlation with neuropathology and clinical features in mice with lymphocytic choriomeningitis.

Authors:  I L Campbell; A Samimi; C S Chiang
Journal:  J Immunol       Date:  1994-10-15       Impact factor: 5.422

View more
  26 in total

1.  CXCR3-dependent plasma blast migration to the central nervous system during viral encephalomyelitis.

Authors:  Cristina P Marques; Parul Kapil; David R Hinton; Claudia Hindinger; Stephen L Nutt; Richard M Ransohoff; Timothy W Phares; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

2.  Programmed death-1 controls T cell survival by regulating oxidative metabolism.

Authors:  Victor Tkachev; Stefanie Goodell; Anthony W Opipari; Ling-Yang Hao; Luigi Franchi; Gary D Glick; James L M Ferrara; Craig A Byersdorfer
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

3.  Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis.

Authors:  Timothy W Phares; Stephen A Stohlman; David R Hinton; Cornelia C Bergmann
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

Review 4.  Immune Surveillance of the CNS following Infection and Injury.

Authors:  Matthew V Russo; Dorian B McGavern
Journal:  Trends Immunol       Date:  2015-10       Impact factor: 16.687

5.  CD4 T cells promote CD8 T cell immunity at the priming and effector site during viral encephalitis.

Authors:  Timothy W Phares; Stephen A Stohlman; Mihyun Hwang; Booki Min; David R Hinton; Cornelia C Bergmann
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

6.  Myd88 Initiates Early Innate Immune Responses and Promotes CD4 T Cells during Coronavirus Encephalomyelitis.

Authors:  Niranjan Butchi; Parul Kapil; Shweta Puntambekar; Stephen A Stohlman; David R Hinton; Cornelia C Bergmann
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

7.  Protective Humoral Immunity in the Central Nervous System Requires Peripheral CD19-Dependent Germinal Center Formation following Coronavirus Encephalomyelitis.

Authors:  Jeffrey R Atkinson; Cornelia C Bergmann
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

8.  Shifting hierarchies of interleukin-10-producing T cell populations in the central nervous system during acute and persistent viral encephalomyelitis.

Authors:  Shweta S Puntambekar; Cornelia C Bergmann; Carine Savarin; Christopher L Karp; Timothy W Phares; Gabriel I Parra; David R Hinton; Stephen A Stohlman
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

Review 9.  Intrathecal humoral immunity to encephalitic RNA viruses.

Authors:  Timothy W Phares; Stephen A Stohlman; Cornelia C Bergmann
Journal:  Viruses       Date:  2013-02-15       Impact factor: 5.048

10.  Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.

Authors:  Helge Frebel; Veronika Nindl; Reto A Schuepbach; Thomas Braunschweiler; Kirsten Richter; Johannes Vogel; Carsten A Wagner; Dominique Loffing-Cueni; Michael Kurrer; Burkhard Ludewig; Annette Oxenius
Journal:  J Exp Med       Date:  2012-12-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.